Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.
about
Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era.Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism.Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients.PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidismPharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Diseases of the parathyroid gland in chronic kidney disease.Cinacalcet: will it play a role in reducing cardiovascular events?The role of FGF23 in CKD--with or without Klotho.Gastric acid, calcium absorption, and their impact on bone health.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.Cinacalcet and Clinical Outcomes in Dialysis.Chronic Kidney Disease-Mineral and Bone Disorder in Asia.Management of secondary hyperparathyroidism: how and why?A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemoUltrasound-based scores as predictors for nodular hyperplasia in patients with secondary hyperparathyroidism: a prospective validation study.Etelcalcetide for the treatment of secondary hyperparathyroidism.Clinical impact of hypercalcemia in kidney transplant.Comparison of oral versus intravenous vitamin D receptor activator in reducing infection-related mortality in hemodialysis patients: the Q-Cohort Study.Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients.Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report.Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.Risk-factors for nodular hyperplasia of parathyroid glands in sHPT patients.A Japanese approach for CKD-MBDClinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism.Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.Parathyroid Nodular Hyperplasia and Responsiveness to Drug Therapy in Renal Secondary Hyperparathyroidism: An Open Question.Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism.Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses.Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism
P2860
Q30316084-89F05198-FBA7-46AD-ADC8-69D7D414CD27Q33878430-B5D304E2-0466-4A30-BF4F-2701167286DAQ34293730-E4BF9778-0A78-428D-BB44-341A06429688Q35051572-376AEEEF-6214-44A5-985F-7CF122951B46Q35658726-8E1DC2B9-68C6-47EA-A66F-E0B0D98CAC31Q36432849-DF855336-DD31-492D-A93F-7EC085F6DFF3Q36620322-68894AC4-8788-4112-8F6A-871A5CBD559DQ36793098-21CAE112-0CF6-41E7-91E2-54B657042CB3Q37095019-812E167F-97C1-4ACD-A82A-1F5E07FD3856Q37891153-614CF0E4-019D-4FD7-B47F-609FB7A32EF4Q37912038-2581453F-29EA-4839-955F-DD2F55956BFFQ37993874-3F2476EC-7BE3-4121-90B8-3479EF633AA2Q38020094-EBBC1F1B-E727-452D-95A3-EC87708DC6B2Q38072903-8263AB04-5B48-4F35-A491-7D835AEC2160Q38092144-9D8897AA-56A8-4583-9976-A793B08CE8ABQ38141236-5BF5FD78-D156-4757-AA0E-07600A87E73AQ38565049-47166168-9326-4DE3-8753-BE3BDA9296B7Q38635767-1EB55CA9-1DE6-4495-A92B-D2E215D9081DQ38775426-6DFA71CD-D0A2-4556-8F97-BB39B5F1D5C4Q39037214-FD870F79-EFE9-4B26-837F-5D3C3206532CQ39039175-E024C34B-F396-4D5B-BE91-EB4FCC9577B3Q39170853-BCBD42AE-BD89-45D4-BA3A-A908E46CA4B5Q39728456-D785B17F-18B3-4ADD-B814-72BAC1C80AECQ40655564-6A6FD168-EB36-42A7-B225-E18BA81AD7B2Q41671380-0493A400-4E44-4261-A22A-1478D149EEBDQ42181616-070DF2DF-6348-4C83-BC4B-E32981F3A80BQ42461866-61627588-2A3A-4BCC-82DB-361DD9B36250Q42683242-F9D6747F-1449-46C8-A615-5AAF50B1D8B1Q42685461-D8B04F45-4EC4-495F-97B5-B1816A33BA48Q42727652-80E5D79B-6C68-4782-972D-30B1EC4FDB62Q43427754-583EA5F9-BD92-40A6-9B3C-32AFEE2CF279Q44227454-80ECF59A-3329-4EE8-A21E-357B3C888100Q46921995-6FC3A2A1-0456-4848-9F16-95D933F96F08Q48239717-ACC93173-2088-4262-AFB1-ED5DDAF48A42Q48417341-7389ED4F-CD8B-4627-A243-7531F5CC3029Q49166621-79128B3C-AE9C-45D4-99CB-3CC62B84B69CQ50789348-9DEF8BC4-FB07-422A-911C-DB076250A99FQ53067680-ECB57571-2685-43C2-892E-944590AF5CFAQ53551519-CC6F42C2-38D9-437B-A433-9EFE4CE2980DQ57218945-2FA33FF7-D746-46D6-B296-C82F0B96D573
P2860
Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@ast
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@en
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@nl
type
label
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@ast
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@en
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@nl
prefLabel
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@ast
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@en
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@nl
P2093
P2860
P356
P1476
Cinacalcet effectively reduces ...... secondary hyperparathyroidism.
@en
P2093
Akira Fujimori
Hirohito Hasegawa
Hirotaka Komaba
Jeongsoo Shin
Koji Shibuya
Masafumi Fukagawa
Masato Nishioka
Motoko Tanaka
Shohei Nakanishi
Takeshi Kurosawa
P2860
P304
P356
10.2215/CJN.02110310
P577
2010-08-26T00:00:00Z